Trial Profile

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Danicopan (Primary) ; Danicopan (Primary) ; Remdesivir
Indications COVID 2019 infections
Focus Proof of concept; Therapeutic Use
Acronyms BET-C

Most Recent Events

26 May 2022 Status changed from recruiting to completed.
29 Nov 2021 Upper and lower age limits have been removed from the Inclusion criteria.
22 Nov 2021 Upper age limit has been added as 99 years to the inclusion criteria.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com